| Year |
Citation |
Score |
| 2023 |
Nguyen MR, Ma E, Wyatt D, Knight KL, Osipo C. The effect of an exopolysaccharide probiotic molecule from on breast cancer cells. Frontiers in Oncology. 13: 1292635. PMID 38074643 DOI: 10.3389/fonc.2023.1292635 |
0.54 |
|
| 2022 |
Nguyen M, Osipo C. Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens. International Journal of Molecular Sciences. 23. PMID 35743256 DOI: 10.3390/ijms23126813 |
0.592 |
|
| 2020 |
BeLow M, Osipo C. Notch Signaling in Breast Cancer: A Role in Drug Resistance. Cells. 9. PMID 33003540 DOI: 10.3390/cells9102204 |
0.66 |
|
| 2020 |
Peiffer DS, Ma E, Wyatt D, Albain KS, Osipo C. DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development. Npj Breast Cancer. 6: 37. PMID 32864429 DOI: 10.1038/s41523-020-00178-5 |
0.372 |
|
| 2020 |
Lesnikoski B, Crozier JA, Srkalovic G, Robinson PA, Osipo C, Banda K, Kling HM, Yoder E, Audeh W. Molecular profiles and treatment recommendations for invasive lobular carcinoma in a real-world prospective breast cancer registry. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E19291 |
0.56 |
|
| 2020 |
Ma E, Zlobin A, Wyatt D, Ng J, Dingwall A, Osipo C. Abstract 1859: Elucidating the role of KMT2D as a novel therapeutic target for resistant HER2+ breast cancer Cancer Research. 80: 1859-1859. DOI: 10.1158/1538-7445.Am2020-1859 |
0.671 |
|
| 2019 |
Peiffer DS, Wyatt D, Zlobin A, Piracha A, Ng J, Dingwall AK, Albain KS, Osipo C. DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy. Cancer Research. PMID 31387918 DOI: 10.1158/0008-5472.Can-19-1110 |
0.571 |
|
| 2019 |
Peiffer D, Wyatt D, Zlobin A, Piracha A, Robinson P, Albain K, Osipo C. Abstract P5-04-10: The role of DAXX on enrichment of breast cancer stem cells from ER+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-04-10 |
0.629 |
|
| 2018 |
Shah D, Wyatt D, Baker A, Simms P, Peiffer DS, Fernandez ML, Rakha EA, Green AR, Filipovic A, Miele L, Osipo C. Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29895705 DOI: 10.1158/1078-0432.Ccr-17-1952 |
0.682 |
|
| 2018 |
Baker A, Wyatt D, Bocchetta M, Li J, Filipovic A, Green A, Peiffer DS, Fuqua S, Miele L, Albain KS, Osipo C. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. PMID 29743588 DOI: 10.1038/S41388-018-0251-Y |
0.724 |
|
| 2018 |
Fukushiro-Lopes DF, Hegel AD, Rao V, Wyatt D, Baker A, Breuer EK, Osipo C, Zartman JJ, Burnette M, Kaja S, Kouzoukas D, Burris S, Jones WK, Gentile S. Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer. Oncotarget. 9: 3321-3337. PMID 29423049 DOI: 10.18632/Oncotarget.22925 |
0.5 |
|
| 2018 |
Robinson PA, Treece T, Osipo C, Qamar R, Zon R, Levine EG, Budway R, Mavromatis BH, Untch S, Bernards R, Audeh MW, Soliman HH. Effect of metabolic syndrome on risk of recurrence and immune pathways in invasive lobular carcinoma disparately compared to ductal. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E24229 |
0.36 |
|
| 2018 |
Zlobin A, Wyatt D, Varsanik M, Dingwall A, Osipo C. Abstract 5845: Roles for MLL2/ KMT2D or MLL3/ KMT2C in HER+ breast cancer stem cells Cancer Research. 78: 5845-5845. DOI: 10.1158/1538-7445.Am2018-5845 |
0.706 |
|
| 2018 |
Wyatt DL, Zlobin A, Ma E, Denning MF, Osipo C. Abstract 1831: PKCδ as a novel target for HER2-positive, trastuzumab resistant breast cancer Cancer Research. 78: 1831-1831. DOI: 10.1158/1538-7445.Am2018-1831 |
0.689 |
|
| 2017 |
Kim JL, Ha GH, Campo L, Denning MF, Patel TB, Osipo C, Lin SY, Breuer EK. The role of Rak in the regulation of stability and function of BRCA1. Oncotarget. 8: 86799-86815. PMID 29156836 DOI: 10.18632/Oncotarget.5717 |
0.487 |
|
| 2017 |
Breuer E, Osipo C, Zartman J, Wells C, Nishimura M, Jones W, Gentile S. Abstract B38: Exploring targeting potassium channels in cancer: A novel strategy for therapeutic intervention Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B38 |
0.484 |
|
| 2017 |
Shah DS, Wyatt D, Baker A, Green A, Filipovic A, Miele L, Osipo C. Abstract 4769: Targeting HER2 enriches Jagged1 high cancer stem cells in breast cancer Cancer Research. 77: 4769-4769. DOI: 10.1158/1538-7445.Am2017-4769 |
0.72 |
|
| 2017 |
Bocchetta M, Osipo C, Sobol A. Abstract 1335: Deubiquitinase OTUD6B isoforms are important regulators of growth and proliferation Cancer Research. 77: 1335-1335. DOI: 10.1158/1538-7445.Am2017-1335 |
0.458 |
|
| 2016 |
Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far. Genes & Diseases. 3: 114-123. PMID 30123819 DOI: 10.1016/J.Gendis.2016.02.002 |
0.701 |
|
| 2016 |
Sobol A, Askonas C, Alani S, Weber MJ, Ananthanarayanan V, Osipo C, Bocchetta M. Deubiquitinase OTUD6B Isoforms are Important Regulators of Growth and Proliferation. Molecular Cancer Research : McR. PMID 27864334 DOI: 10.1158/1541-7786.Mcr-16-0281-T |
0.417 |
|
| 2016 |
Nunes J, Zhang H, Angelopoulos N, Chhetri J, Osipo C, Grothey A, Stebbing J, Giamas G. ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget. PMID 27050377 DOI: 10.18632/Oncotarget.8504 |
0.464 |
|
| 2016 |
Shah D, Osipo C. Abstract P3-06-15: Notch3 as a predictor of GSI sensitivity in distinct subtypes of triple negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-06-15 |
0.663 |
|
| 2016 |
Zlobin A, Wyatt D, Bloodworth JC, Hilsenbeck S, Fuqua S, Miele L, Albain KS, Osipo C. Abstract LB-121: DAXX is a novel Notch-1 gene target and biomarker of GSI-sensitivity in ER+ breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-121 |
0.62 |
|
| 2016 |
Baker AT, Pandya K, Osipo C. Abstract 2124: Notch-1 mediated down regulation of PTEN in trastuzumab resistant HER2+ breast cancer Cancer Research. 76: 2124-2124. DOI: 10.1158/1538-7445.Am2016-2124 |
0.833 |
|
| 2016 |
Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far Genes and Diseases. 3: 114-123. DOI: 10.1016/j.gendis.2016.02.002 |
0.645 |
|
| 2015 |
Pandya K, Wyatt D, Gallagher B, Bloodworth JC, Shah D, Baker A, Zlobin A, Pannuti A, Green AR, Ellis IO, Filipovic A, Sagert J, Rana A, Albain KS, Miele L, ... ... Osipo C, et al. PKCα Attenuates Jagged-1-mediated Notch Signaling in ErbB-2 positive Breast Cancer to Reverse Trastuzumab Resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26350262 DOI: 10.1158/1078-0432.CCR-15-0179 |
0.797 |
|
| 2015 |
Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival. The Journal of Biological Chemistry. 290: 21705-12. PMID 26152725 DOI: 10.1074/Jbc.M115.655563 |
0.662 |
|
| 2015 |
Albain KS, Zlobin AY, Covington KR, Gallahger BT, Hilsenbeck SG, Czerlanis CM, Lo S, Robinson PA, Gaynor ER, Godellas C, Bova D, Czaplicki K, Busby B, Stiff PJ, Fuqua SA, ... ... Osipo C, et al. Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S4-03 |
0.647 |
|
| 2015 |
Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A. Human epidermal growth factor receptor 2 (HER2) impedes MLK3 kinase activity to support breast cancer cell survival Journal of Biological Chemistry. 290: 21705-21712. DOI: 10.1074/jbc.M115.655563 |
0.505 |
|
| 2014 |
Baker AT, Zlobin A, Osipo C. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Frontiers in Oncology. 4: 360. PMID 25566499 DOI: 10.3389/Fonc.2014.00360 |
0.613 |
|
| 2014 |
Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MA, Franzen CA, Gupta GN, Osipo C, Zlobin A, Syn WK, Zhang J, Kuo PC, Mi Z. Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene. PMID 25531323 DOI: 10.1038/Onc.2014.410 |
0.382 |
|
| 2014 |
Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Rana B, Rana A. Abstract 1829: Regulation of Mixed Lineage Kinase-3 activity by Her2 and its implication in death or survival Cancer Research. 74: 1829-1829. DOI: 10.1158/1538-7445.Am2014-1829 |
0.613 |
|
| 2014 |
Osipo C, Pandya K, Wyatt D. Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy Cancer Research. 74: 1823-1823. DOI: 10.1158/1538-7445.Am2014-1823 |
0.819 |
|
| 2014 |
Pandya K, Osipo C. Gene amplification of ErbB-2: From gene to therapy Medical Radiology. 63: 7-13. DOI: 10.1007/174_2014_1048 |
0.551 |
|
| 2013 |
Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, et al. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2: e60. PMID 23917222 DOI: 10.1038/oncsis.2013.26 |
0.682 |
|
| 2013 |
Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Oncotargets and Therapy. 6: 943-55. PMID 23901284 DOI: 10.2147/Ott.S33766 |
0.694 |
|
| 2013 |
Speiser JJ, Erşahin C, Osipo C. The functional role of Notch signaling in triple-negative breast cancer. Vitamins and Hormones. 93: 277-306. PMID 23810012 DOI: 10.1016/B978-0-12-416673-8.00013-7 |
0.675 |
|
| 2013 |
Pekmezci M, Szpaderska A, Osipo C, Erşahin Ç. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas. International Journal of Surgical Pathology. 21: 126-32. PMID 23204031 DOI: 10.1177/1066896912467370 |
0.518 |
|
| 2013 |
Olsauskas-Kuprys R, Osipo C. Abstract 861: Analysis of predictive genes in triple negative breast cancer in response to a gamma-secretase inhibitor. Cancer Research. 73: 861-861. DOI: 10.1158/1538-7445.Am2013-861 |
0.623 |
|
| 2013 |
Zlobin A, Kuprys-Olsauskas R, Shah D, Osipo C. Abstract P6-05-25: Ratio of notch receptors is critical for response to notch inhibition by a gamma-secretase inhibitor in triple negative breast cancer cells Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P6-05-25 |
0.704 |
|
| 2012 |
Pekmezci M, Szpaderska A, Osipo C, Erşahin C. The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma. Pathology Research International. 2012: 947041. PMID 22482085 DOI: 10.1155/2012/947041 |
0.413 |
|
| 2012 |
Lai M, Meeke K, Osipo C. Abstract 939: ErbB-2 inhibits Notch-4 expression and activity in breast cancer independent of ER function Cancer Research. 72: 939-939. DOI: 10.1158/1538-7445.Am2012-939 |
0.708 |
|
| 2012 |
Pandya K, Osipo C. Abstract 909: ErbB-2 restricts Mib-1 and Jagged-1 association to inhibit Notch-1 activation in ErbB-2 positive breast cancer Cancer Research. 72: 909-909. DOI: 10.1158/1538-7445.Am2012-909 |
0.796 |
|
| 2012 |
Osipo C, Baumgartner A, Zlobin A, O'Toole M. Abstract P4-08-06: Notch-dependent Regulation of Novel Genes Associated with Trastuzumab Resistance Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-08-06 |
0.614 |
|
| 2012 |
Zlobin A, Olsauskas-Kuprys R, Hodge S, O'Toole M, Ersahin C, Osipo C. Abstract P2-05-15: Assessment of Notch Signaling Pathway Components as Biomarkers for Triple Negative Breast Cancer: Comparison of Triple Negative Breast Cancer Cell Lines and Human Breast Cancer Samples. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-05-15 |
0.671 |
|
| 2011 |
Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer. 105: 796-806. PMID 21847123 DOI: 10.1038/Bjc.2011.321 |
0.802 |
|
| 2011 |
Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Research : Bcr. 13: R63. PMID 21679465 DOI: 10.1186/Bcr2900 |
0.819 |
|
| 2011 |
Pandya K, Meeke K, Rogowski A, Clementz A, Osipo C. Abstract 2553: Inhibition of γ-secretase in combination with Lapatinib induces tumor regressionin vivo Cancer Research. 71: 2553-2553. DOI: 10.1158/1538-7445.Am2011-2553 |
0.791 |
|
| 2011 |
Rogowski AS, Osipo C. Abstract 2284: Investigation of notch-1, ErbB-2, and ERα crosstalk in breast cancer Cancer Research. 71: 2284-2284. DOI: 10.1158/1538-7445.Am2011-2284 |
0.703 |
|
| 2010 |
Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. Targeting Notch to target cancer stem cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3141-52. PMID 20530696 DOI: 10.1158/1078-0432.Ccr-09-2823 |
0.49 |
|
| 2010 |
Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene. 29: 201-13. PMID 19838210 DOI: 10.1038/Onc.2009.323 |
0.647 |
|
| 2010 |
Mehta K, Meeke K, Patel P, Miele L, Osipo C. Abstract 614: ErbB-2 Suppresses Notch-1 Signaling by Regulating Jagged-1 Localization in ErbB-2 positive breast cancer Cancer Research. 70: 614-614. DOI: 10.1158/1538-7445.Am10-614 |
0.719 |
|
| 2010 |
Clementz AG, Rizzo P, Miele L, Osipo C. Abstract 3918: PEA3 is a novel transcriptional activator of Notch-1 and Notch-4 in breast cancer: Opportunity for a new combination strategy Cancer Research. 70: 3918-3918. DOI: 10.1158/1538-7445.Am10-3918 |
0.839 |
|
| 2009 |
Mehta K, Osipo C. Trastuzumab resistance: role for Notch signaling. Thescientificworldjournal. 9: 1438-48. PMID 20024517 DOI: 10.1100/Tsw.2009.166 |
0.636 |
|
| 2009 |
Clementz AG, Osipo C. Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I? Breast Cancer Research : Bcr. 11: 110. PMID 19849815 DOI: 10.1186/Bcr2407 |
0.819 |
|
| 2009 |
Rizzo P, Osipo C, Pannuti A, Golde T, Osborne B, Miele L. Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer. Advances in Enzyme Regulation. 49: 134-41. PMID 19344631 DOI: 10.1016/J.Advenzreg.2009.01.008 |
0.597 |
|
| 2009 |
Mehta K, Meeke K, Clementz A, Albain K, Osipo C. Notch-1 Confers Resistance to ErbB-2 Targeted Inhibition by Regulating PTEN, p27, and IGF-1R. Cancer Research. 69: 3123-3123. DOI: 10.1158/0008-5472.Sabcs-09-3123 |
0.613 |
|
| 2008 |
Chi A, Yun J, Osipo C, Rizzo P, Wyatt D, Sabou A, Albuquerque K, Miele L. The additive effects of gamma secretase inhibitor and ionizing radiation in MDA-MD-231 breast cancer cell line. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14594. PMID 27950086 DOI: 10.1200/Jco.2008.26.15_Suppl.14594 |
0.655 |
|
| 2008 |
Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 27: 5124-31. PMID 18758481 DOI: 10.1038/Onc.2008.226 |
0.591 |
|
| 2008 |
Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research. 68: 5226-35. PMID 18593923 DOI: 10.1158/0008-5472.Can-07-5744 |
0.699 |
|
| 2008 |
Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 27: 5019-32. PMID 18469855 DOI: 10.1038/Onc.2008.149 |
0.823 |
|
| 2008 |
Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Laboratory Investigation; a Journal of Technical Methods and Pathology. 88: 11-7. PMID 18059366 DOI: 10.1038/Labinvest.3700700 |
0.318 |
|
| 2008 |
Rizzo P, Osipo C, Foreman K, Yun J, Golde T, Osborne B, Miele L. Rational Targeting of Notch in Breast Cancer Aacr Education Book. 2008: 491-495. DOI: 10.1158/Aacr.Edb-08-8135 |
0.64 |
|
| 2008 |
Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches (Cancer Research (July 1, 2008) 68 (5226-5235)) Cancer Research. 68: 7246. DOI: 10.1158/0008-5472.Can-68-17-Cor1 |
0.582 |
|
| 2008 |
Miele L, Rizzo P, Osipo C, Foreman K, Bocchetta M, Tonetti D. 6 INVITED Notch as a potential therapeutic target in cancer European Journal of Cancer Supplements. 6: 4. DOI: 10.1016/S1359-6349(08)71938-4 |
0.444 |
|
| 2007 |
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 30: 509-20. PMID 17203234 DOI: 10.3892/Ijo.30.2.509 |
0.571 |
|
| 2006 |
Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. International Journal of Oncology. 29: 1237-46. PMID 17016657 DOI: 10.3892/Ijo.29.5.1237 |
0.612 |
|
| 2006 |
O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2255-63. PMID 16609042 DOI: 10.1158/1078-0432.Ccr-05-2584 |
0.622 |
|
| 2005 |
Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Journal of the National Cancer Institute. 97: 1746-59. PMID 16333030 DOI: 10.1093/Jnci/Dji400 |
0.596 |
|
| 2005 |
Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL, Gartenhaus RB. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Research. 65: 10651-6. PMID 16322206 DOI: 10.1158/0008-5472.Can-05-0845 |
0.607 |
|
| 2005 |
Jordan VC, Lewis JS, Osipo C, Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast (Edinburgh, Scotland). 14: 624-30. PMID 16202599 DOI: 10.1016/J.Breast.2005.08.022 |
0.535 |
|
| 2005 |
Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC. Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. Cancer Research. 65: 8504-13. PMID 16166331 DOI: 10.1158/0008-5472.Can-04-4107 |
0.415 |
|
| 2005 |
Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal Journal of Steroid Biochemistry and Molecular Biology. 94: 131-141. PMID 15862958 DOI: 10.1016/J.Jsbmb.2004.12.032 |
0.557 |
|
| 2005 |
Osipo C, Gajdos C, Cheng D, Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. The Journal of Steroid Biochemistry and Molecular Biology. 93: 249-56. PMID 15860267 DOI: 10.1016/J.Jsbmb.2004.12.005 |
0.547 |
|
| 2004 |
Osipo C, Liu H, Meeke K, Jordan VC. The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Experimental Biology and Medicine (Maywood, N.J.). 229: 722-31. PMID 15337826 DOI: 10.1177/153537020422900804 |
0.63 |
|
| 2003 |
Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D, Liu H. Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast (Edinburgh, Scotland). 12: 432-41. PMID 14659118 DOI: 10.1016/S0960-9776(03)00149-8 |
0.666 |
|
| 2003 |
Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. Journal of the National Cancer Institute. 95: 1597-608. PMID 14600092 DOI: 10.1093/Jnci/Djg079 |
0.643 |
|
| 2003 |
Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. Journal of the National Cancer Institute. 95: 1586-97. PMID 14600091 DOI: 10.1093/Jnci/Djg080 |
0.679 |
|
| 2002 |
Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells Gynecologic Oncology. 85: 498-506. PMID 12051881 DOI: 10.1006/Gyno.2002.6659 |
0.486 |
|
| 2001 |
Osipo C, Dorman S, Frankfater A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors Experimental Cell Research. 264: 388-396. PMID 11262195 DOI: 10.1006/Excr.2000.5121 |
0.322 |
|
| Show low-probability matches. |